AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]
This study is a single arm, multi-center phase II study of AZD 2811 monotherapy in patients with relapsed small cell lung cancer (SCLC) as a second or third line therapy.

Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
Small Cell Lung Cancer
DRUG: AZD2811
Objective reponse rate (ORR) by RECIST 1.1, Assessments to be performed using CT or MRI scans. To be measured, up to 18months
Duration of response, Assessments to be performed using CT or MRI scans. To be measured, up to 18months|Disease control rate, Assessments to be performed using CT or MRI scans. To be measured, At 8 weeks|Overall survival(OS), Kaplan-Meier method, up to 18 months|Progression-free survival(PFS), Kaplan-Meier method, up to 18 months
Number of participants with Adverse Events as Assessed by CTCAE v4.03, CTCAE v4.03, up to 18months
This study is a single arm, multi-center phase II study of AZD 2811 monotherapy in patients with relapsed small cell lung cancer (SCLC) as a second or third line therapy.

Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.